Iranian Society of Gynecology Oncology


Obstetrics & Gynecology Department, Medicine Faculty, Iran University of Medical Sciences, Tehran, Iran


Aims: The rate of induced abortion is growing worldwide. In this study, we aimed at comparing using misoprostol with or without Letrozole in abortion.
Materials and Methods: In this placebo-controlled trial, 46 women with a gestational age of fewer than 20 weeks, who were candidates of legal abortion, were selected by simple randomization sampling method and randomly assigned into two groups. Drug group received 10mg daily Letrozole (4 tablets of 2.5mg) for 3 days prior to taking Misoprostol and the placebo group received daily placebo (4 tablets with the exact appearance of Letrozole) with the same instructions. After 3 days, Misoprostol was given to all the participants based on their gestational ages. The data were analyzed by SPSS 16 software, using independent sample t-test and Chi-square test.
Findings: 21 women (45.7%) had a successful complete abortion, and curettage was needed for 25 women (54.3%). Successful abortion rate was significantly higher in the group receiving Letrozole (78.3%) than the group receiving placebo (13.0%; p=0.0001). Mean induction-abortion interval was 22.61±7.721 hours in the drug group and 24.09±8.251 hours in the placebo group, which was not significantly different (p>0.05). There was no significant difference between the two groups in terms of vaginal bleeding and adverse effects.
Conclusion: Using 10mg daily Letrozole for 3 days followed by oral Misoprostol results in a significantly higher rate of complete abortion compared with placebo in women with a gestational age of less than 20 weeks.


  1. Grimes DA, Stuart G. Abortion jabberwocky: The need for better terminology. Contraception. 2010;81(2):93-6. [DOI:10.1016/j.contraception.2009.09.005] [PMID]
  2. Sedgh G, Bearak J, Singh S, Bankole A, Popinchalk A, Ganatra B, et al. Abortion incidence between 1990 and 2014: Global, regional, and subregional levels and trends. Lancet. 2016;388(10041):258-67. [DOI:10.1016/S0140-6736(16)30380-4]
  3. Berer M. Abortion law and policy around the world: In search of decriminalization. Health Hum Rights. 2017;19(1):13-27.
  4. Shah I, Ahman E. Unsafe abortion: Global and regional incidence, trends, consequences, and challenges. J Obstet Gynaecol Can. 2009;31(12):1149-58. [DOI:10.1016/S1701-2163(16)34376-6]
  5. Naghshineh E, Allame Z, Farhat F. The effectiveness of using misoprostol with and without Letrozole for successful medical abortion: A randomized placebo-controlled clinical trial. J Res Med Sci. 2015;20(6):585-9. [DOI:10.4103/1735-1995.165964] [PMID]
  6. Kulier R, Kapp N, Gulmezoglu AM, Hofmeyr GJ, Cheng L, Campana A. Medical methods for first trimester abortion. Cochrane Database Syst Rev. 2011;(11):CD002855. [DOI:10.1002/14651858.CD002855.pub4] [PMID]
  7. Ho PC, Blumenthal PD, Gemzell-Danielsson K, Gomez Ponce de Leon R, Mittal S, Tang OS. Misoprostol for the termination of pregnancy with a live fetus at 13 to 26 weeks. Int J Gynaecol Obstet. 2007;99 Suppl 2:S178-81. [DOI:10.1016/j.ijgo.2007.09.007] [PMID]
  8. Tanha FD, Golgachi T, Niroomand N, Ghajarzadeh M, Nasr R. Sublingual versus vaginal misoprostol for second trimester termination: A randomized clinical trial. Arch Gynecol Obstet. 2013;287(1):65-9. [DOI:10.1007/s00404-012-2508-y] [PMID]
  9. American College of Obstetricians and Gynecologists. Practice bulletin no, 143: Medical management of first-trimester abortion. Obstet Gynecol. 2014;123(3):676-92. [DOI:10.1097/01.AOG.0000444454.67279.7d] [PMID]
  10. Wildschut H, Both MI, Medema S, Thomee E, Wildhagen MF, Kapp N. Medical methods for mid-trimester termination of pregnancy. Cochrane Database Syst Rev. 2011;(1):CD005216. [DOI:10.1002/14651858.CD005216.pub2] [PMID]
  11. Cohen MH, Johnson JR, Li N, Chen G, Pazdur R. Approval summary: Letrozole in the treatment of postmenopausal women with advanced breast cancer. Clin Cancer Res. 2002;8(3):665-9.
  12. BIG 1-98 Collaborative Group, Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Thürlimann B, Paridaens R, et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med. 2009;361(8):766-76. [DOI:10.1056/NEJMoa0810818] [PMID]
  13. World Health Organization. clinical practice handbook for safe abortion. Geneva: World Health Organization; 2014.
  14. Yeung TW, Lee VC, Ng EH, Ho PC. A pilot study on the use of a 7-day course of letrozole followed by misoprostol for the termination of early pregnancy up to 63 days. Contraception. 2012;86(6):763-9. [DOI:10.1016/j.contraception.2012.05.009] [PMID]
  15. Chai J, Ho PC. A pilot study on the combined use of letrozole, mifepristone and misoprostol in termination of first trimester pregnancy up to 9 weeks' gestation. Eur J Obstet Gynecol Reprod Biol. 2013;171(2):291-4. [DOI:10.1016/j.ejogrb.2013.09.017] [PMID]
  16. Lee VC, Tang OS, Ng EH, Yeung WS, Ho PC. A prospective double-blinded, randomized, placebo-controlled trial on the use of letrozole pretreatment with misoprostol for second-trimester medical abortion. Contraception. 2011;84(6):628-33. [DOI:10.1016/j.contraception.2011.03.012] [PMID]
  17. Lee VC, Ng EH, Yeung WS, Ho PC. Misoprostol with or without letrozole pretreatment for termination of pregnancy: A randomized controlled trial. Obstet Gynecol. 2011;117(2 Pt 1):317-23. [DOI:10.1097/AOG.0b013e3182073fbf] [PMID]
  18. Behroozi-Lak T, Derakhshan-Aydenloo S, Broomand F. Evaluation of effect of letrozole prior to misoprostol in comparison with misoprostol alone in success rate of induced abortion. J Gynecol Obstet Hum Reprod. 2018;47(3):113-7. [DOI:10.1016/j.jogoh.2017.11.002] [PMID]